Lecanemab received FDA approval in January after a phase 3 trial showed it slows cognitive decline in early-stage Alzheimer's ...

The FDA has recently approved exciting new treatments that can slow the progression of Alzheimer’s disease, a scourge that claims more American lives than breast cancer and prostate cancer combined.

The vote essentially upheld the Food and Drug Administration’s earlier rulings, with some members calling for new clinical ...

An advisory committee to the U.S. Food and Drug Administration unanimously rejected a drug-and-device combination made by a ...

Approved by the FDA earlier this year, the Alzheimer's therapy lecanemab is an antibody that reduces the buildup in the brain of a sticky peptide called amyloid-beta (Aβ), which is thought to be ...

The Food and Drug Administration is now regularly approving new drugs after just one or two clinical trials — a significant departure from the more rigorous vetting process the agency was ...

A potential new Alzheimer’s drug represses the harmful inflammatory response of the brain’s immune cells, reducing disease pathology, preserving neurons, and improving cognition in preclinical tests.

Scientists at Oregon Health and Science University have made a development that could lead to a greater understanding of ...

An outside panel of experts to the U.S. Food and Drug Administration on Wednesday backed the expanded use of Alnylam Pharmaceuticals' gene silencing drug to treat a type of heart disease associated ...

We’ll send you a myFT Daily Digest email rounding up the latest Vivek Ramaswamy news every morning. US biotech company Roivant Sciences has moved to distance itself from its founder, Vivek ...

For decades, attempts to treat or slow Alzheimer's disease (AD) — a brain disorder that causes dementia through damage to brain cells and other changes in the brain — have been dispiriting ...

Use one of the services below to sign in to PBS: You've just tried to add this video to My List. But first, we need you to sign in to PBS using one of the services below. You've just tried to add ...